title: Acquired Glanzmann's thrombasthenia with optimal response to rituximab therapy.
authors.affiliation: Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA. solhx001@umn.edu
authors.forename: Melhem
authors.initials: M
authors.lastname: Solh
authors.forename: Craig
authors.initials: C
authors.lastname: Mescher
authors.forename: Anthony
authors.initials: A
authors.lastname: Klappa
authors.forename: Surbhi
authors.initials: S
authors.lastname: Shah
authors.forename: Nicole
authors.initials: N
authors.lastname: Zantek
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Datta
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control; D004238:Diverticulitis / Q000150:complications / Q000601:surgery; D004351:Drug Resistance; D004438:Ecchymosis / Q000209:etiology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D000069283:Rituximab; D013915:Thrombasthenia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab